Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 3
2015 1
2016 3
2017 1
2020 1
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.
Paracchini L, Mannarino L, Romualdi C, Zadro R, Beltrame L, Fuso Nerini I, Zola P, Laudani ME, Pagano E, Giordano L, Fruscio R, Landoni F, Franceschi S, Dalessandro ML, Canzonieri V, Bocciolone L, Lorusso D, Bosetti C, Raspagliesi F, Garassino IMG; TOWARDS group; D'Incalci M, Marchini S. Paracchini L, et al. Among authors: fuso nerini i. Sci Transl Med. 2023 Dec 6;15(725):eadi2556. doi: 10.1126/scitranslmed.adi2556. Epub 2023 Dec 6. Sci Transl Med. 2023. PMID: 38055801 Free article.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R. Bizzaro F, et al. Among authors: fuso nerini i. J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x. J Hematol Oncol. 2021. PMID: 34742344 Free PMC article.
Role of macrophage targeting in the antitumor activity of trabectedin.
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Germano G, et al. Among authors: fuso nerini i. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008. Cancer Cell. 2013. PMID: 23410977 Free article.
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, Panini N, Colombo M, Blouw B, Kang DW, Davoli E, Zucchetti M, D'Incalci M, Frapolli R. Morosi L, et al. Among authors: fuso nerini i. J Exp Clin Cancer Res. 2021 Sep 10;40(1):286. doi: 10.1186/s13046-021-02070-x. J Exp Clin Cancer Res. 2021. PMID: 34507591 Free PMC article.
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
Calura E, Fruscio R, Paracchini L, Bignotti E, Ravaggi A, Martini P, Sales G, Beltrame L, Clivio L, Ceppi L, Di Marino M, Fuso Nerini I, Zanotti L, Cavalieri D, Cattoretti G, Perego P, Milani R, Katsaros D, Tognon G, Sartori E, Pecorelli S, Mangioni C, D'Incalci M, Romualdi C, Marchini S. Calura E, et al. Among authors: fuso nerini i. Clin Cancer Res. 2013 Aug 1;19(15):4114-23. doi: 10.1158/1078-0432.CCR-13-0360. Epub 2013 Jun 13. Clin Cancer Res. 2013. PMID: 23766361
Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
Cesca M, Morosi L, Berndt A, Fuso Nerini I, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S, D'Incalci M, Davoli E, Zucchetti M, Giavazzi R. Cesca M, et al. Among authors: fuso nerini i. Mol Cancer Ther. 2016 Jan;15(1):125-35. doi: 10.1158/1535-7163.MCT-15-0063. Epub 2015 Oct 22. Mol Cancer Ther. 2016. PMID: 26494857
14 results